Alzheimer's disease

Biogen shares rise 1.06% to $193.40 despite FDA extending Leqembi review to August 2026, offset by $5.6B Apellis acquisition and Spinraza approval momentum.

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.

FDA extends LEQEMBI IQLIK subcutaneous review to August 2026 without raising approvability concerns, maintaining regulatory momentum for Eisai and Biogen's reformulated Alzheimer's treatment.

INmune Bio reported Q1 2026 net loss of $5.4M, down from $9.7M year-ago. Company advancing XPro for Alzheimer's with $21.4M cash on hand.

Acumen Pharma to present at BofA Securities conference May 14 ahead of late-2026 Alzheimer's drug trial results.

Acumen Pharmaceuticals to report Q1 2026 results May 12, with Phase 2 Alzheimer's drug data expected later this year.

Vaccinex released 2025 financial results while launching Phase 2b Alzheimer's study, advancing its antibody therapy pipeline for neurodegenerative diseases and cancer.

Tiziana Life Sciences reports positive preclinical data for intranasal foralumab in treating Long COVID neuroinflammation and cognitive dysfunction.

Biogen's three-decade outperformance is challenged by biosimilar competition and weak growth, though new Alzheimer's and rare disease drugs offer hope. Success requires flawless execution.

Global dementia market expanding rapidly as disease-modifying treatments like LEQEMBI and KISUNLA shift focus from symptom management to early intervention for 55 million affected patients worldwide.

AC Immune and Eli Lilly amend collaboration to advance tau-targeting Alzheimer's candidates, with $11M upfront and IND studies starting mid-2026.

Acumen Pharmaceuticals will report full-year 2025 financial results on March 26, 2026, as its lead Alzheimer's candidate progresses through Phase 2 trials.

INmune Bio's XPro trial gains recognition at AD/PD 2026 for innovative biomarker-enriched Alzheimer's approach, securing FDA approval to advance to Phase 2b/3 registrational studies.

Acumen Pharmaceuticals to present Alzheimer's drug candidate sabirnetug at Stifel CNS Forum on March 18, 2026, as Phase 2 trials advance.

Alzheimer's therapeutics market projected to exceed $6B by 2026 driven by rising disease prevalence and increased pharma investment in disease-modifying treatments.